

## Paritaprevir

CASRN: 1216941-48-8

*Chemical structure for Paritaprevir*

*FULL RECORD DISPLAY*

*Displays all fields in the record.*

*For other data, click on the Table of Contents*

### Drug Levels and Effects:

Summary of Use during Lactation:

Paritaprevir has not been studied **in nursing** mothers being treated for hepatitis C infection. Because it is greater than 97% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. If paritaprevir used alone or in combination with ombitasvir and ritonavir (Technivie) or with ombitasvir, desabuvir and ritonavir (Viekira Pak) is required by the mother, it is not a reason to discontinue breastfeeding. Some sources recommend against breastfeeding when **paritaprevir** is used with ribavirin.

Hepatitis C is not transmitted through breastmilk[1][2] and **breastmilk** has been shown to inactivate hepatitis C virus (HCV).[3][4] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply **to mothers** who are being treated for hepatitis C.

Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, **nucleic acid testing is recommended**. [1][2]

Drug Levels:

Maternal Levels. Relevant published information *was not found* as of the revision date.

Infant Levels. Relevant published information **was not found as of the revision** date.

Effects in Breastfed Infants:

Relevant published information **was not found as of the revision date**.

Effects on Lactation and Breastmilk:

Relevant published information was not found as of the [revision date](#).

[Alternate Drugs to Consider:](#)

[\(Hepatitis C\) Interferon Alfa](#), **Interferon Alfacon**, Peginterferon Alfa

References:

1. Cottrell EB , Chou R, Wasson N et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. [Ann Intern Med](#). 2013;158:109-13. PMID: 23437438
2. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. [MMWR Recomm Rep](#). 2015;64:1-137. PMID: 26042815
3. Pfaender S, Heyden J, Friesland M et al. Inactivation of hepatitis C virus infectivity by human breast milk. [J Infect Dis](#). 2013;208:1943-52. PMID: 24068703
4. Tovo PA, Calitri C, Scolfaro C et al. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. [World J Gastroenterol](#). 2016;22:1382-92. PMID: 26819507

Substance **Identification:**

**Substance Name:**

**Paritaprevir**

CAS Registry Number:

1216941-48-8

Drug Class:

Antiviral Agents

**Protease Inhibitors**

**Administrative Information:**

LactMed **Record Number:**

1241

Last Revision Date:

20160707

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.